Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neurofibromatosis 1 12Neurofibroma, Plexiform 6Carcinoma, Non-Small-Cell Lung 4Neurofibrosarcoma 3Neoplasms 3Lung Neoplasms 3Melanoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 14Nivolumab 11Ipilimumab 10cabozantinib 6Axitinib 6belzutifan 5Radiosurgery 5atezolizumab 4Sunitinib 4palbociclib 3lenvatinib 3Surveys and Questionnaires 3Radiotherapy 3Pluvicto 3Everolimus 3Blood Specimen Collection 3Biopsy 3zimberelimab 2pazopanib 2cemiplimab 2Therapeutics 2Methods 2Magnetic Resonance Spectroscopy 2Irinotecan 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2trebananib 1toripalimab 1tocilizumab 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × AZD 6244 × 1 year × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡